Aspira Women's Health Inc. reported its financial results for the first quarter of 2025, revealing a revenue increase to approximately $2.28 million, up from $2.15 million in the same period of 2024, marking a 5.9% growth. The rise was primarily attributed to select price increases implemented during the quarter. The company also highlighted a 94% increase in sales per full-time equivalent salesperson compared to the first quarter of 2024, driven by strategic changes in market approach by the new executive team. Gross profit improved significantly, reaching approximately $1.6 million, a 28.5% increase from $1.2 million in the previous year. Gross margins increased to 68.5% from 56.4%, benefiting from a one-time reduction in accruals and enhanced profitability of the OvaWatch® product line. Operating expenses saw a notable reduction, declining to $4.8 million, a 19% decrease from $5.9 million in the same period of the prior year. This was primarily due to a $0.8 million decrease in selling expenses and a $0.4 million reduction in general and administrative expenses, partially offset by a $0.1 million increase in research and development expenses. The company reported a net loss of $1.853 million for the quarter, an improvement from the $4.629 million loss in the first quarter of 2024. The cash used in operations decreased to $3.1 million, representing a 30% reduction in operating cash burn from the previous year. In terms of business updates, Aspira emphasized its focus on executing an aggressive research and development timeline for ENDOInform™, with expectations to provide significant updates by the end of 2025. The company remains dedicated to advancing non-invasive diagnostic tools for gynecologic diseases, including ongoing developments in its ovarian cancer and endometriosis testing portfolios.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspira Women's Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1029192) on May 19, 2025, and is solely responsible for the information contained therein.
Comments